User login
Key clinical point: Androgen receptor amplification (ARamp) status is associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who receive novel hormonal treatment (NHT) but not in those treated with taxanes.
Major finding: Patients with ARamp or PTEN aberrations (PTENalt) vs those without had worse relative PSA response with NHT vs taxanes. The presence of ARamp, PTENalt, or RB1 aberrations was associated with worse time to next treatment and overall survival with NHT without affecting clinical benefit from taxane therapy.
Study details: A retrospective study of 308 patients with mCRPC who received treatment between 2011 and 2020.
Disclosures: This work was sponsored by Foundation Medicine. Some authors disclosed employment with Foundation Medicine and/or stock ownership in Roche. The authors received speaker/consulting/ advisory fees, research funding, and/or honoraria outside this work.
Source: Graf RP et al. Eur Urol. 2021 Oct 26. doi: 10.1016/j.eururo.2021.09.030.
Key clinical point: Androgen receptor amplification (ARamp) status is associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who receive novel hormonal treatment (NHT) but not in those treated with taxanes.
Major finding: Patients with ARamp or PTEN aberrations (PTENalt) vs those without had worse relative PSA response with NHT vs taxanes. The presence of ARamp, PTENalt, or RB1 aberrations was associated with worse time to next treatment and overall survival with NHT without affecting clinical benefit from taxane therapy.
Study details: A retrospective study of 308 patients with mCRPC who received treatment between 2011 and 2020.
Disclosures: This work was sponsored by Foundation Medicine. Some authors disclosed employment with Foundation Medicine and/or stock ownership in Roche. The authors received speaker/consulting/ advisory fees, research funding, and/or honoraria outside this work.
Source: Graf RP et al. Eur Urol. 2021 Oct 26. doi: 10.1016/j.eururo.2021.09.030.
Key clinical point: Androgen receptor amplification (ARamp) status is associated with clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who receive novel hormonal treatment (NHT) but not in those treated with taxanes.
Major finding: Patients with ARamp or PTEN aberrations (PTENalt) vs those without had worse relative PSA response with NHT vs taxanes. The presence of ARamp, PTENalt, or RB1 aberrations was associated with worse time to next treatment and overall survival with NHT without affecting clinical benefit from taxane therapy.
Study details: A retrospective study of 308 patients with mCRPC who received treatment between 2011 and 2020.
Disclosures: This work was sponsored by Foundation Medicine. Some authors disclosed employment with Foundation Medicine and/or stock ownership in Roche. The authors received speaker/consulting/ advisory fees, research funding, and/or honoraria outside this work.
Source: Graf RP et al. Eur Urol. 2021 Oct 26. doi: 10.1016/j.eururo.2021.09.030.